Peptide Initiative

Peptide profile · Weight Management

Exenatide

First-in-class GLP-1 receptor agonist derived from Gila monster venom (Byetta/Bydureon), FDA-approved for type 2 diabetes with demonstrated cardiovascular safety in the 14,752-patient EXSCEL trial and available in both twice-daily and once-weekly formulations

Strong human trialsFDA approved for this use
Byetta: ~2.4 hoursHalf-life (immediate-release); Bydureon: ~7 weeks effective duration via PLGA microsphere technology; Tmax ~2.1 hours (Byetta)
65–75% after subcutaneous injectionBioavailability (Byetta); microsphere sustained release for Bydureon
4,187Molecular weight, Da

Molecular formula

C184H282N50O60S

CAS number
183321-74-6
PubChem
45588096
Developed · 1992 (discovery); 2005 (Byetta FDA approval); 2012 (Bydureon FDA approval)
Dr. John Eng / Amylin Pharmaceuticals, AstraZeneca (originally Amylin Pharmaceuticals)

Amino acid sequence

HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Blood Sugar ControlWorks like a key that unlocks your body's natural insulin release, but only when blood sugar is high, which helps prevent dangerous lows .

9.4

Weight LossSlows down digestion and sends fullness signals to your brain, helping most people lose around 5 to 11 pounds over time .

8.6

Heart SafetyA major study of nearly 15,000 people showed it doesn't increase heart attack or stroke risk, even in those with heart disease .

8.2

Ratings out of 10.

0.005 – 2mg

Every documented dose level

PhaseDoseFrequency
First 1 month5 mcgTwice daily, within 60 minutes before the two main meals
Ongoing10 mcgTwice daily, within 60 minutes before the two main meals
Ongoing chronic therapy2 mgOnce weekly
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit & patients preferring once-weekly dosing convenience (bydureon 2 mg) over daily injections for improved adherence

Best for

  • Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit

    Exenatide is particularly well-suited for individuals focused on type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence

    Exenatide is particularly well-suited for individuals focused on patients preferring once-weekly dosing convenience (bydureon 2 mg) over daily injections for improved adherence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain

    Exenatide is particularly well-suited for individuals focused on overweight or obese type 2 diabetes patients (bmi >27) requiring glycemic control without weight gain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety

    Exenatide is particularly well-suited for individuals focused on patients with established cardiovascular disease who need a glp-1 ra with demonstrated cardiovascular safety. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for weight management supportConsult your healthcare provider for alternatives to Exenatide based on your specific needs and medical history
Alternative weight management approachesSemaglutide (Wegovy/Ozempic)Liraglutide (Saxenda)AOD-9604
Non-injectable weight managementOral semaglutide (Rybelsus)Phentermine-topiramate (Qsymia)Lifestyle modifications

Do not use if

  • Prior serious hypersensitivity reaction to exenatide or any excipient
  • Severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease — the Byetta label says it is not recommended in these patients
  • Extended-release exenatide only (Bydureon, now withdrawn in the US): personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. The immediate-release label carries no such contraindication and no boxed warning .

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Exenatide use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Exenatide with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Exenatide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Exenatide is an FDA-approved GLP-1 receptor agonist with post-market safety data spanning 15+ years, though some safety concerns have emerged.

Nausea affects 30-45% of patients, dose-dependent and typically improves within 1-2 weeks but can lead to treatment discontinuation in 5% of patients. Pancreatitis risk, while rare (0.1-0.2%), is increased and contraindicated in patients with history of acute pancreatitis.

Benign thyroid C-cell adenomas were seen in rats across all exenatide doses in a 104-week carcinogenicity study, but this appears only in the Nonclinical Toxicology section: the immediate-release label (Byetta) carries no boxed warning and does not contraindicate medullary thyroid cancer or MEN 2.

That contraindication belonged to extended-release Bydureon, which no longer has a current US label. Acute kidney injury has been reported in 0.3-1% of patients, particularly with concurrent NSAID or ACE inhibitor use.

Hypoglycemia risk is minimal when used as monotherapy but increases substantially when combined with insulin or sulfonylureas.

Exenatide was studied in Phase 3 trials (DURATION program) for type 2 diabetes with long-term safety data spanning 5-10 years in individual trials.

Multiple post-market surveillance studies and comparative efficacy trials with other GLP-1 agonists (particularly semaglutide) provide evidence of its safety profile.

The preclinical thyroid C-cell findings and post-market pancreatitis reports have led to specific monitoring recommendations and contraindication protocols.


Common side effects · experienced by some users

Nausea

Most frequent adverse effect — 44% with Byetta, 25–30% with Bydureon. Typically mild to moderate, most pronounced during initial weeks and dose escalation .

Management
Gradual dose titration (5→10 mcg over 1 month for Byetta). Eat smaller meals. Avoid fatty foods. Nausea generally improves with continued use. Bydureon has lower nausea rates than Byetta.

Vomiting and diarrhea

Vomiting in 10–15% and diarrhea in 12–15% of patients. GI effects are dose-related and more common with the immediate-release formulation .

Management
Stay well hydrated. If severe, temporarily maintain current dose rather than escalating. Consider switching to Bydureon for better GI tolerability.

Injection site nodules (Bydureon)

Subcutaneous nodules at injection sites occur in 5–10% of Bydureon users due to the microsphere depot formulation. Usually painless and self-resolving.

Management
Rotate injection sites regularly. Nodules typically resolve over weeks as microspheres are absorbed. No treatment usually required.

Decreased appetite and constipation

Reduced appetite (therapeutic for weight management) and constipation (10–20%) are common GI effects of GLP-1 receptor activation .

Management
Appetite reduction is expected and therapeutic. Constipation managed with adequate fiber and fluid intake.

Serious side effects

Acute pancreatitis

Acute pancreatitis reported in 0.2% of EXSCEL participants. FAERS pharmacovigilance data shows significant pancreatitis signal with exenatide. Potentially life-threatening.

Management
Discontinue exenatide immediately if pancreatitis suspected (severe persistent abdominal pain). Monitor amylase/lipase. Do not restart after confirmed pancreatitis.

Renal impairment

Acute kidney injury reported rarely, typically associated with severe dehydration from GI side effects (vomiting, diarrhea). Exenatide is renally cleared .

Management
Ensure adequate hydration. Monitor renal function. Contraindicated in eGFR <15. Use with caution in moderate renal impairment (eGFR 15–29).

Less commonHypoglycemia

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Exenatide
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Exenatide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeMetformin (first-line combination with additive glycemic benefit — extensively studied in AMIGO and DURATION trials) — May be used together under medical guidance.
  • SafeSGLT2 inhibitors such as empagliflozin or dapagliflozin (complementary weight loss and cardiovascular mechanisms) — May be used together under medical guidance.
  • SafeBasal insulin (glargine or degludec) — once-weekly exenatide plus daily basal insulin is a convenient, effective combination with careful hypoglycemia monitoring — May be used together under medical guidance.

With medications

  • CautionOther GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) — redundant mechanism with increased adverse effects — Use with caution—discuss with your healthcare provider.
  • CautionDPP-4 inhibitors (sitagliptin, saxagliptin) — overlapping incretin pathway; no additional benefit over exenatide alone — Use with caution—discuss with your healthcare provider.
  • CautionSulfonylureas at full dose — increased hypoglycemia risk; reduce sulfonylurea dose when initiating exenatide — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Exenatide. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs weeks 1-4 (initiation and titration)

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Gradual

(3-4 weeks)


How it works

Exenatide (Byetta/Bydureon) is a first-in-class GLP-1 hormone derived from Gila monster venom that helps control blood sugar and reduces weight by increasing insulin release, suppressing glucagon, and promoting satiety—available as both twice-daily and once-weekly injections.

The deeper mechanism

Exenatide is a 39-amino acid synthetic peptide identical to exendin-4, a naturally occurring GLP-1 receptor agonist from Gila monster (Heloderma suspectum) venom.

With 53% amino acid homology to human GLP-1 but a critical Gly2 substitution (vs Ala2 in native GLP-1), exenatide resists DPP-4 enzymatic degradation, conferring a 2.4-hour half-life (Byetta) or ~7 weeks via poly(D,L-lactide-co-glycolide) microsphere formulation (Bydureon).

Exenatide binds to and activates the GLP-1 receptor (Kd ~136 pM, ~4-fold higher affinity than native GLP-1) on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppresses postprandial glucagon, delays gastric emptying, and promotes satiety through hypothalamic GLP-1 receptor activation.


What to expect

  1. Weeks 1-4 (initiation and titration)

    What you might notice

    • Reduced appetite and early feelings of fullness, especially after meals
    • Nausea that may be prominent during the first 1–2 weeks (up to 44% with Byetta)
    • Initial improvements in postprandial blood glucose readings
    • Modest early weight loss (0.5–1 kg) from reduced caloric intake

    What's normal

    • GI side effects are most common during this phase — this is the primary reason for gradual titration
    • Glycemic improvements begin but may be modest at the 5 mcg starting dose
    • For Bydureon, a small subcutaneous nodule at the injection site is expected (microsphere depot)
    • Blood glucose monitoring should be more frequent during this adjustment period

    What's next

    • Increase Byetta from 5 to 10 mcg after 1 month if well tolerated
    • For Bydureon, steady state drug levels build over 4–8 weeks — be patient with initial response
    • GI side effects should begin improving by week 2–3
  2. Weeks 4-16 (dose optimization)

    What you might notice

    • More significant HbA1c improvement as maintenance dose takes full effect
    • Progressive weight loss (1–3 kg total by 12–16 weeks)
    • Significant improvement or resolution of initial GI side effects
    • Improved postprandial blood glucose control throughout the day

    What's normal

    • Bydureon reaches full steady state by week 6–8, so maximum efficacy develops gradually
    • Weight loss continues steadily with maintained appetite suppression
    • HbA1c should show measurable improvement (0.5–1.0% reduction) by 12 weeks
    • Injection site nodules with Bydureon are benign and gradually resolve

    What's next

    • Evaluate overall glycemic and weight response at 16 weeks
    • If additional glycemic control needed, consider adding basal insulin or SGLT2 inhibitor
    • Continue current therapy if goals are being met
  3. Months 4-12+ (long-term maintenance)

    What you might notice

    • Sustained glycemic control with HbA1c reduction of 0.8–1.5% from baseline
    • Stable weight loss of 2–5 kg maintained over months to years
    • Well-tolerated therapy with minimal ongoing side effects
    • DURATION studies show efficacy maintained through 5+ years of continuous use

    What's normal

    • Weight loss rate naturally plateaus after initial months — this is expected metabolic adaptation
    • Glycemic benefits remain stable with continued therapy
    • Cardiovascular safety established through EXSCEL for long-term use
    • Periodic monitoring of HbA1c, renal function, and lipids recommended

    What's next

    • Continue long-term therapy with periodic metabolic assessment
    • If glycemic targets not met, consider intensifying with insulin or switching to higher-efficacy GLP-1 RA
    • Annual comprehensive metabolic and cardiovascular risk assessment

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Exenatide over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

353 registered studies, 9 still enrolling.

353registered studies
9recruiting now
174phase 3 or 4
166with published results

By phase

Phase 4

83

Phase 3

82

Phase 2

48

Phase 1

42

Phase 1/2

13

Phase 2/3

9

Early Phase 1

5

No phase

71

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

328

Records only

25

About 65,835 people took part in the studies that actually administered Exenatide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT07497399 Phase 2Recruiting120 enrolled

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Johns Hopkins University

  • NCT07347080 Early Phase 1Recruiting9 enrolled

    A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

    The First Affiliated Hospital of Henan University of Science and Technology

  • CHDR2418

    Centre for Human Drug Research

See all 353 trials for Exenatide

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Exenatide is named as an intervention; studies that only mention it in passing are not.

How was exenatide discovered from Gila monster venom?

Dr. John Eng, an endocrinologist at the Miami VA Medical Center, discovered exendin-4 in Gila monster (Heloderma suspectum) venom in 1992 while studying how this lizard maintains glucose homeostasis during prolonged fasting between infrequent meals. Exendin-4 turned out to be a potent GLP-1 receptor agonist naturally resistant to the DPP-4 enzyme that rapidly degrades human GLP-1, making it an ideal drug candidate for type 2 diabetes.

What is the difference between Byetta and Bydureon?

Both contain exenatide but differ in formulation and dosing. Byetta is immediate-release exenatide (5–10 mcg injected twice daily before meals) that provides acute prandial glucose control. Bydureon uses poly(D,L-lactide-co-glycolide) microsphere technology to deliver 2 mg exenatide once weekly, providing sustained GLP-1 receptor activation with lower nausea rates and improved patient adherence.

What did the EXSCEL cardiovascular trial show?

EXSCEL enrolled 14,752 type 2 diabetes patients (73% with prior cardiovascular disease) across 688 sites in 35 countries. After a median 3.2 years of follow-up, once-weekly exenatide was noninferior to placebo for cardiovascular safety (MACE HR 0.91, 95% CI 0.83–1.00). While it met the safety endpoint, it did not demonstrate statistically significant cardiovascular superiority (P=0.06 for superiority).

Can exenatide be used in children?

Yes, Bydureon BCise was approved in 2020 for pediatric patients aged 10–17 years with type 2 diabetes as an adjunct to diet and exercise. This makes exenatide one of the few GLP-1 receptor agonists with an approved pediatric indication.

How does exenatide compare to newer GLP-1 receptor agonists?

Exenatide was the first GLP-1 RA and has the longest safety track record. However, newer agents like semaglutide offer greater HbA1c reduction and weight loss. Meta-analyses show semaglutide > dulaglutide > exenatide for overall efficacy. Exenatide's advantages include its established safety record, two formulation options (BID and weekly), and the pediatric indication for Bydureon BCise.

Why does exenatide cause more nausea than some other GLP-1 agonists?

Byetta (immediate-release) causes more nausea (~44%) because it produces rapid, high peak plasma concentrations that strongly activate GLP-1 receptors in the area postrema (nausea center). Bydureon (extended-release) has lower nausea rates (25–30%) because the microsphere formulation provides gradual, sustained release without sharp peaks. Newer long-acting GLP-1 RAs also tend to have lower nausea rates for similar reasons.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Exenatide, on one page.

Exenatide dosing protocol

Medical disclaimer

Exenatide is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

0.005 – 2 mg Twice daily, within 60 minutes before the two main meals or once weekly · onset 3-4 weeks
Open the Exenatide calculatorExenatide calculator